1401966-32-2Relevant academic research and scientific papers
Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor
Wang, Xiaowen,Su, Mingbo,Li, You,Liu, Tongchao,Wang, Yujie,Chen, Yabing,Tang, Le,He, Yu-Peng,Ding, Xiaoguang,Yu, Fang,Shen, Jingkang,Li, Jia,Zhou, Yubo,Chen, Yue-Lei,Xiong, Bing
, p. 844 - 847 (2019)
Tranylcypromine moiety extracted from LSD1 inhibitors and 6-trifluoroethyl thienopyrimidine moiety from menin-MLL1 PPI inhibitors were merged to give new chemotypes for medicinal chemistry study. Among 15 new compounds prepared in this work, some exhibited nanomolar LSD1 activity and good selectivity over MAO-A/B, low micromolar menin-MLL1 PPI inhibitory activity, as well as submicromolar MV4-11 antiprofilative activities. Intracellular LSD1 engagement of compounds with higher enzymatic and antiproliferative activities was confirmed by CD86 mRNA up-regulation experiments.
Cyclopropylamines as LSD1 inhibitors
-
Page/Page column 39; 40; 41, (2016/06/14)
This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
LSD1 Fluorocyclopropylamine as inhibitor
-
Paragraph 0165, (2016/10/09)
This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
